A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.13/3650 |
Resumo: | Cancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new che motherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side effects, for example by a change in drug's pharmacokinetics, cell targeting and/or specific stimuli-responsive ness. This is the case of doxorubicin (DOX) that presents a broad spectrum of activity and is one of the most widely used chemotherapeutic drugs as first-line treatment. Indeed, DOX is a very interesting example of a drug for which several nanosized delivery systems have been developed over the years. While it is true that some of these systems are already in the market, it is also true that research on this subject remains very active and that there is a continuing search for new solutions. In this sense, this review takes the example of doxorubicin, not so much with the focus on the drug itself, but rather as a case study around which very diverse and imaginative nanotechnology approaches have emerged. |
id |
RCAP_2afec3aa6e4432b0825f053e937c23e6 |
---|---|
oai_identifier_str |
oai:digituma.uma.pt:10400.13/3650 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the marketCancerChemotherapyDoxorubicinNanotherapeuticsDelivery systemsClinical trials.Faculdade de Ciências Exatas e da EngenhariaCentro de Química da MadeiraCancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new che motherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side effects, for example by a change in drug's pharmacokinetics, cell targeting and/or specific stimuli-responsive ness. This is the case of doxorubicin (DOX) that presents a broad spectrum of activity and is one of the most widely used chemotherapeutic drugs as first-line treatment. Indeed, DOX is a very interesting example of a drug for which several nanosized delivery systems have been developed over the years. While it is true that some of these systems are already in the market, it is also true that research on this subject remains very active and that there is a continuing search for new solutions. In this sense, this review takes the example of doxorubicin, not so much with the focus on the drug itself, but rather as a case study around which very diverse and imaginative nanotechnology approaches have emerged.ElsevierDigitUMaGonçalves, MaraMignani, SergeRodrigues, JoãoTomás, Helena2021-09-22T09:11:04Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.13/3650engGonçalves, M., Mignani, S., Rodrigues, J., & Tomás, H. (2020). A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. Journal of Controlled Release, 317, 347-374. https://doi.org/10.1016/j.jconrel.2019.11.01610.1016/j.jconrel.2019.11.016info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-24T05:11:45Zoai:digituma.uma.pt:10400.13/3650Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-03-24T05:11:45Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market |
title |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market |
spellingShingle |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market Gonçalves, Mara Cancer Chemotherapy Doxorubicin Nanotherapeutics Delivery systems Clinical trials . Faculdade de Ciências Exatas e da Engenharia Centro de Química da Madeira |
title_short |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market |
title_full |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market |
title_fullStr |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market |
title_full_unstemmed |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market |
title_sort |
A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market |
author |
Gonçalves, Mara |
author_facet |
Gonçalves, Mara Mignani, Serge Rodrigues, João Tomás, Helena |
author_role |
author |
author2 |
Mignani, Serge Rodrigues, João Tomás, Helena |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
DigitUMa |
dc.contributor.author.fl_str_mv |
Gonçalves, Mara Mignani, Serge Rodrigues, João Tomás, Helena |
dc.subject.por.fl_str_mv |
Cancer Chemotherapy Doxorubicin Nanotherapeutics Delivery systems Clinical trials . Faculdade de Ciências Exatas e da Engenharia Centro de Química da Madeira |
topic |
Cancer Chemotherapy Doxorubicin Nanotherapeutics Delivery systems Clinical trials . Faculdade de Ciências Exatas e da Engenharia Centro de Química da Madeira |
description |
Cancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new che motherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side effects, for example by a change in drug's pharmacokinetics, cell targeting and/or specific stimuli-responsive ness. This is the case of doxorubicin (DOX) that presents a broad spectrum of activity and is one of the most widely used chemotherapeutic drugs as first-line treatment. Indeed, DOX is a very interesting example of a drug for which several nanosized delivery systems have been developed over the years. While it is true that some of these systems are already in the market, it is also true that research on this subject remains very active and that there is a continuing search for new solutions. In this sense, this review takes the example of doxorubicin, not so much with the focus on the drug itself, but rather as a case study around which very diverse and imaginative nanotechnology approaches have emerged. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020 2020-01-01T00:00:00Z 2021-09-22T09:11:04Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.13/3650 |
url |
http://hdl.handle.net/10400.13/3650 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Gonçalves, M., Mignani, S., Rodrigues, J., & Tomás, H. (2020). A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. Journal of Controlled Release, 317, 347-374. https://doi.org/10.1016/j.jconrel.2019.11.016 10.1016/j.jconrel.2019.11.016 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1817542901654093824 |